Ranking Important Factors for Using Postoperative Chemotherapy in Non-Muscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC)
Overactive BladderUro-Oncology
Related content
Overactive BladderUro-Oncology
Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer
Int J Urol.
Kobatake K, Hayashi T, Black PC, Goto K, Sentani K, Kaneko M, Yasui W, Mita K, Teishima J, Matsubara A
doi: 10.1111/iju.13389.
Uro-Oncology
Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme
Eur Urol.
Mariappan P, Johnston A, Padovani L, Clark E, Trail M, Hamid S, Hollins G, Simpson H, Thomas BG, Hasan R, Bhatt J, Ahmad I, Nandwani GM, Mitchell IDC, Hendry D, for members of the Scottish Bladder Cancer QPI Research Collaborative
doi: 10.1016/j.eururo.2020.06.051.
Uro-Oncology
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin
Eur Urol.
Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM
doi: 10.1016/j.eururo.2020.02.012.
Uro-Oncology
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
Eur Urol.
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V
doi: 10.1016/j.eururo.2019.08.016.
Further Publications Urology
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
Eur Urol
Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, Bründl J, van der Kwast TH, Brisuda A, Rubio-Briones J, Seles M, Hentschel AE, Kusuma VRM, Huebner N, Cotte J, Mertens LS, Volanis D, Cussenot O, Subiela Henríquez JD, de la Peña E, Pisano F, Pešl M, van der Heijden AG, Herdegen S, Zlotta AR, Hacek J, Calatrava A, Mannweiler S, Bosschieter J, Ashabere D, Haitel A, Côté JF, El Sheikh S, Lunelli L, Algaba F, Alemany I, Soria F, Runneboom W, Breyer J, Nieuwenhuijzen JA, Llorente C, Molinaro L, Hulsbergen-van de Kaa CA, Evert M, Kiemeney LALM, N'Dow J, Plass K, Čapoun O, Soukup V, Dominguez-Escrig JL, Cohen D, Palou J, Gontero P, Burger M, Zigeuner R, Mostafid AH, Shariat SF, Rouprêt M, Compérat EM, Babjuk M, van Rhijn BWG
doi: 10.1016/j.eururo.2020.12.033
Uro-Oncology
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
Eur Urol.
Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG
doi: 10.1016/j.eururo.2020.03.055.
Uro-Oncology
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
Eur Urol.
Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V
doi: 10.1016/j.eururo.2019.09.029.
Overactive BladderUro-Oncology
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials
Eur Urol
Burdett S, Fisher DJ, Vale CL, Bono AV, Clarke NW, Cognetti F, Collette L, Cote RJ, Goebell PJ, Groshen S, Lehmann J, Parmar MKB, Rolevich AI, Sonntag RW, Sternberg CN, Stockle M, Studer UE, Torti FM, Zhegalik AG, Tierney JF, Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group.
doi: 10.1016/j.eururo.2021.09.028
Overactive BladderUro-Oncology
An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups
Urol Oncol.
Bosschieter J, Nieuwenhuijzen JA, Vis AN, van Ginkel T, Lissenberg-Witte BI, Beckers GMA, van Moorselaar RJA
doi: 10.1016/j.urolonc.2018.05.026.